BioreclamationIVT, a New York provider of biospecimens, today announced the acquisition of Detroit-based Asterand Bioscience located in the Tech One Building at the north end of Midtown in TechTown. Asterand Bioscience is a global provider of human tissue and oncology-focused research solutions.
Asterand Bioscience researches ways to speed up identification and biomarker validation of drug targets. They also improve the selection of drug candidates for clinical success using their worldwide network of 75 active collaborative donor institutions.
“We are delighted that Asterand Bioscience’s talented staff is joining BioreclamationIVT,” says Jeff Gatz, BioreclamationIVT’s CEO. “This acquisition will expand BioreclamationIVT’s portfolio of highly-annotated disease-state biospecimens. After combining Asterand Bioscience’s first-rate oncology tissue sourcing network with our existing strength in procuring disease-state tissue and clinical biofluids, BioreclamationIVT will become the market leader in disease-state biospecimens and a top resource for researchers focused on precision medicine.”
BioreclamationIVT specializes in control and disease-state matrices manufactured from human and animal specimens. Following a recent expansion, they now offer cell processing and phenotypic screening services. BioreclamationIVT is currently focused on expanding their industry through targeted investments and continued M&A transactions.
“The addition of Asterand Bioscience’s tissue services and PhaseZERO research services groups will allow the combined company to offer a full research workflow solution, ranging from specimen sourcing through experimental design to data collection,” adds Gatz. “BioreclamationIVT’s new offerings will include target and biomarker validation using histology and molecular techniques, and compound evaluation using cell-based model systems.”
Asterand Bioscience was founded in 2006 through the merger of Asterand, a human tissue biobank, and Pharmagene, a human tissue-based drug discovery company. They also have offices in the United Kingdom.